Mesoblast secures $50M from a new 5-year loan to retire costly short-term debt and fund growth.

Mesoblast Limited has drawn $50 million from a new five-year loan facility provided by a shareholder, replacing higher-cost short-term debt. This move strengthens Mesoblast's balance sheet by lowering interest costs and removing short-term obligations, allowing more flexibility for strategic partnerships. The loan has an 8% fixed interest rate and is secured only by a royalty asset, without encumbering key company assets or intellectual property. Mesoblast remains well-funded to support its commercial operations and development pipeline in cellular medicines for inflammatory diseases.